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Safety and effectiveness of medication abortion provided via
telemedicine at Planned Parenthood in four U.S. states
Kohn JEa, Snow JLa, Simons HRa, Seymour JWb, Thompson TAb,
Grossman Dc
aPlanned Parenthood Federation of America, New York, NY, USA
bIbis Reproductive Health, Cambridge, MA, USA
cAdvancing New Standards in Reproductive Health (ANSIRH), UCSF, San
Francisco, CA, USA
Introduction: To evaluate the safety and effectiveness of medica-
tion abortion provided via telemedicine compared to standard
medication abortion at Planned Parenthood health centers in four
U.S. states.
Methods: Telemedicine patients visited a health center and met
with a clinician remotely via secure telemedicine platform. We
analyzed electronic health record data for patients at 26 health
centers in Alaska, Idaho, Nevada, and Washington from April 2017
through March 2018. We compared occurrence of ongoing preg-
nancy and receipt of or referral for an aspiration procedure between
groups. We performed logistic regression adjusting for gestational
age and health center clustering. We also reviewed all medication
abortion-related adverse event reports submitted during this time
period for the same health centers. We calculated frequencies and
rates of clinically signiﬁcant adverse events for both groups.
Results: Across the 26 health centers, 5,952 patients received a
medication abortion during the study period (738 telemedicine and
5,214 standard). The mean gestational age was 49.0 days (50.4 days
telemedicine vs. 48.9 days standard, pb0.001). Overall, we had
outcome data for 4,456 (74.7%) of patients who followed up with the
health center within 45 days of the abortion: 445 (60.2%)
telemedicine patients and 4,011 (76.8%) standard patients
(pb0.001). Among patients with follow-up data, 1.6% had an ongoing
pregnancy: 0.5% of telemedicine and 1.8% of standard medication
abortion patients (adjusted OR=0.23 [95% CI 0.14–0.39]). Overall,
4.2% of patients received or were referred for an aspiration
procedure: 1.4% of telemedicine and 4.5% of standard medication
abortion patients (adjusted OR=0.28 [95% CI 0.17–0.46]). Fewer
than one percent of patients in each group reported clinically
signiﬁcant adverse events associated with medication abortion
during the study period. No deaths were reported.
Conclusion: Findings from this study conducted across geograph-
ically-diverse settings support existing evidence that medication
abortion provided via telemedicine is safe and effective.
doi:10.1016/j.contraception.2019.03.008
Pharmacists’ knowledge of medication abortion and attitudes
towards mifepristone dispensing at the pharmacy
Raifman Sa, Kaller Sa, Baba CFa, Averbach Sb, Creinin MDc, Meckstroth Ka,
Raﬁe Sb, Raine-Bennett Td, Grossman Da
aUCSF, San Francisco, CA, USA
bUCSD, San Diego, CA, USA
cUC Davis, Sacramento, CA, USA
dKaiser Permanente Northern California, Oakland, CA, USA
Introduction: Pharmacy dispensing of mifepristone could expand
access to medication abortion (MA) by enabling clinicians who
cannot or will not stock the medications in their facility to provide
MA. Little is known about US pharmacists’ knowledge and attitudes
about mifepristone dispensing.
Method: Pharmacists employed at six hospital outpatient and
retail pharmacies in California and Washington participating in a
study of mifepristone pharmacy dispensing completed a baseline
self-administered online survey to assess support for pharmacy
dispensing of MA, beneﬁts and challenges of implementing this
model, personal plans to dispense, and knowledge of MA.
Results: Forty-eight pharmacists completed baseline surveys;
respondents were more commonly female (60%) and had a range
of years of practice (median=12, range 0-41). Only one respondent
elected not to dispense mifepristone in the study due to religious
objections. Most pharmacists were “very supportive” (n=25, 52%) or
“somewhat supportive” (n=15, 31%) of the model and said it would
be “somewhat easy” (n=25, 52%) or “very easy” (n=5, 10%) to
implement. Commonly reported potential beneﬁts included im-
proved access to MA (n=41, 84%), streamlined medication delivery
(n=35, 71%), and expanded pharmacist role in providing reproduc-
tive health services (n=36, 73%); one pharmacist, who planned to
dispense mifepristone, indicated no beneﬁts. Commonly anticipated
challenges to implementing this model included potential pharma-
cist refusal to dispense due to personal objections (n=39, 80%) and
lack of familiarity with mifepristone (n=27, 55%); four (8%)
pharmacists did not anticipate any challenges. Although most
pharmacists (n=39, 81%) were aware of misoprostol’s mechanism
of action in MA, 24 (50%) understood how mifepristone works to
effect abortion, 20 (42%) knew the dosage and route of administra-
tion, 13 (27%) knew the approved gestational age limit, and 15 (31%)
knew the MA regimen effectiveness.
Conclusions: Despite having little involvement in MA to date,
pharmacists at study sites have some knowledge about MA, are
supportive of pharmacy dispensing of mifepristone, and plan to
dispense when given the opportunity. Educational outreach to
pharmacists about MA is recommended in anticipation of removal
of dispensing restrictions. Additional research on attitudes in a
broader pharmacist population is needed.
doi:10.1016/j.contraception.2019.03.009
Comprehension of a Mifepristone–Misoprostol OTC Label for
Medical Abortion: A Pilot Study
Kapp Na, Eckersberger Ea, Methazia Jb, Bessenaar Tb
aIpas, Chapel Hill, Chapel Hill, NC, USA
bIbis Reproductive Health, Johannesburg, South Africa
Introduction: As an important step in developing an over-the-
counter (OTC) product, this study assesses how well women
understand a prototype label for a mifepristone-misoprostol regimen
for abortion.
Method: We conducted a prospective, non-randomized pilot
study utilizing convenience sampling to enroll women in rural and
urban communities at four sites in two South African provinces.
Potential participants were prescreened and consented by trained,
female recruiters. Included women were aged 16-45 with some
literacy (assessed by REALM-R). Exclusion criteria were having ever
used or assisted someone with a medical abortion. Demographic data
were collected after enrolment. Women were given as much time as
needed to read the prototype label, then asked a series of 35
questions to assess key concepts for correct use of the drug. For all
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